Labetuzumab Govitecan (CEACAM5/CEA/CD66e) Antibody, Monoclonal | 10-727

Labetuzumab Govitecan (CEACAM5/CEA/CD66e) Antibody, Monoclonal | 10-727 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Humanized / CEACAM5/CEA/CD66e [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-kappa

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: IMMU-130, hMN-14-SN-38, hMN-14-SN-38 ADC, hMN14-CL-SN-38

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Labetuzumab govitecan (IMMU-130) is an antibody drug conjugate that integrates anti-CEACAM5 antibody labetuzumab with cytotoxic drugs (http://www.chemdrug.com/) SN-38. Carcinoembryonic antigens corresponding to antibodies can be detected in plasma (http://www.chemdrug.com/sell/76/) and have high expression in many solid tumors (especially CRC) .